Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.18EUR
23 Feb 2018
Change (% chg)

€-0.43 (-4.94%)
Prev Close
€8.60
Open
€8.60
Day's High
€8.68
Day's Low
€7.82
Volume
2,520,614
Avg. Vol
483,999
52-wk High
€16.88
52-wk Low
€7.28

Select another date:

BRIEF-Almirall Sees 20 Pct EBITDA Growth In 2018

* FY EBITDA 142.2 MILLION EUROS VERSUS 227.6 MILLION EUROS YEAR AGO

BRIEF-Almirall FY Net Result Turns To Loss Of 304 Million Euros

* FY NET LOSS 304.0 MILLION EUROS VERSUS PROFIT OF 75.5 MILLION EUROS YEAR AGO

BRIEF-Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain

* EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN)

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

BRIEF-Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​

* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​

BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​

* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​ Source text for Eikon:

Spain's Almirall warns of delay in approval for psoriasis drug

Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

Spain's Almirall warns of delay in approval for psoriasis drug

Nov 14 Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

BRIEF-Almirall 9-month net result turns to loss of 99.7 mln euros YoY

* 9-MONTH EBITDA 100.1 MILLION EUROS VERSUS 183.8 MILLION EUROS YEAR AGO

BRIEF-Almirall ends phase III research for nail psoriasis product in Europe

* TERMINATES ITS RESEARCH ACTIVITIES FOR P3073 PROGRAM (NAIL PSORIASIS) IN EUROPE IN PHASE III OF DEVELOPMENT ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: